EVP/CMO Brams Matthew buys 1,946 shares at $5.04; 3 other insiders also bought within 14 days—cluster pattern amid unprofitable fundamentals.
Brams Matthew, EVP and Chief Medical Officer of Cingulate Inc., purchased 1,946 shares at $5.04 on 2026-02-06, increasing his post-transaction holdings to 4,656 shares (+71.8% vs pre-transaction holdings of 2,710 shares). This transaction occurred within a broader pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated or reinforcing insider confidence. However, the company's fundamentals present a critical counterpoint—net income was $-7,341,062.00 over the most recent full fiscal year, and market cap stands at $46,083,217.40, indicating a pre-revenue or unprofitable-stage entity. The transaction price of $5.04 sits 26.1% below the current price of $6.82, and the stock has risen +47.3% over 30 days and +79.5% over 90 days, suggesting recent momentum. Investors should note the apparent disconnect: multiple insiders are buying into a materially unprofitable business experiencing sharp recent appreciation.